腔内影像学方法评价降脂治疗对冠状动脉粥样硬化斑块影响的研究进展

doi:10.16352/j.issn.1001-6325.2022.03.032

摘要/Abstract

摘要： 动脉粥样硬化斑块与动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular diseases, ASCVD)的发生及发展密切相关。借助腔内影像学,如血管内超声(intravascular ultrasound, IVUS)、光学相干成像(optical coherence tomography, OCT)和近红外光谱成像(near-infrared spectroscopy, NIRS)可以更为清晰显示斑块大小、体积及细微形态学特征。有研究证实降胆固醇药物通过降低低密度脂蛋白胆固醇(low-density lipoprotein-cholesterol, LDL-C)水平等途径可实现斑块稳定甚至逆转。本文旨在对采用腔内影像学方法观察降胆固醇治疗对ASCVD患者斑块影响的相关研究作一综述。

关键词: 腔内影像学, 血管内超声, 光学相干成像, 近红外光谱成像, 降胆固醇治疗, 动脉粥样硬化斑块

Abstract: The progression of atherosclerotic plaque is one of the most important causes of cardiovascular events in patients with atherosclerotic cardiovascular diseases (ASCVD). With the help of intravascular imaging, such as intravascular ultrasound (IVUS), optical coherence tomography (OCT) and near-infrared spectroscopy (NIRS), it is possible to show the details of the plaque morphological characteristics. Current research suggested that lipid-lowering drugs lead to plaque stabilization and regression mainly by reducing low-density lipoprotein cholesterol (LDL-C). This review focuses on the effects of lipid-lowering therapy on coronary atherosclerotic plaque evaluated by intravascular imaging.

Key words: intravascular imaging, intravascular ultrasound(IVUS), optical coherence tomography(OCT), near-infrared spectroscopy(NIRS), lipid-lowing therapy, atherosclerotic plaque

中图分类号:

R541.6

张爽, 李之凡, 钱杰, 吴娜琼. 腔内影像学方法评价降脂治疗对冠状动脉粥样硬化斑块影响的研究进展[J]. 基础医学与临床, 2022, 42(3): 366-371.

ZHANG Shuang, LI Zhi-fan, QIAN Jie, WU Na-qiong. Effects of lipid-lowering therapy on coronary atherosclerotic plaque evaluated by intravascular imaging[J]. Basic & Clinical Medicine, 2022, 42(3): 366-371.

参考文献

[1]TAKATA K, IMAIZUMI S, ZHANG B, et al. Stabiliza-tion of high-risk plaques[J]. Cardiovasc Diagn Ther, 2016, 6: 304-321.
[2]MINTZ GS, GUAGLIUMI G. Intravascular imaging in coronary artery disease[J]. Lancet, 2017, 390: 793-809.
[3]GILI S, IANNACCONE M, COLOMBO F, et al. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry[J]. Eur Heart J Cardiovasc Imaging, 2018, 19: 524-531.
[4]AHMADI A, ARGULIAN E, LEIPSIC J, et al. From subclinical atherosclerosis to plaque progression and acute coronary events: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2019, 74: 1608-1617.
[5]WAKSMAN R, DI MARIO C, TORGUSON R, et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study[J]. Lancet, 2019, 394: 1629-1637.
[6]SCHUURMAN AS, VROEGINDEWEY M, KARDYS I, et al. Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up[J]. Eur Heart J, 2018, 39: 295-302.
[7]NISSEN SE, NICHOLLS SJ, SIPAHI I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial[J]. JAMA, 2006, 295: 1556-1565.
[8]PURI R, LIBBY P, NISSEN SE, et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN[J]. Eur Heart J Cardiovasc Imaging, 2014, 15: 380-388.
[9]PARK SJ, KANG SJ, AHN JM, et al. Effect of statin treatment on modifying plaque composition: adouble-blind, randomized study[J]. J Am Coll Cardiol, 2016, 67: 1772-1783.
[10]PURI R, NICHOLLS SJ, SHAO M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression[J]. J Am Coll Cardiol, 2015, 65: 1273-1282.
[11]KOVARNIK T, MINTZ GS, SKALICKA H, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study[J]. Circ J, 2012, 76: 176-183.
[12]HOUGAARD M, HANSEN HS, THAYSSEN P, et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial[J]. Cardiovasc Revasc Med, 2017, 18: 110-117.
[13]TSUJITA K, SUGIYAMA S, SUMIDA H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutane-ous coronary intervention: the multicenter randomized controlled PRECISE-IVUS Trial[J]. J Am Coll Cardiol, 2015, 66: 495-507.
[14]LEE JH, SHIN DH, KIM BK, et al. Early effects of intensive lipid-lowering treatment on plaque characteristics assessed by virtual histology intravascular ultrasound[J]. Yonsei Med J, 2016, 57: 1087-1094.
[15]MASUDA J, TANIGAWA T, YAMADA T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease[J]. Int Heart J, 2015, 56: 278-285.
[16]UEDA Y, HIRO T, HIRAYAMA A, et al. Effect of ezetimibe on stabilization and regression of intracoronary plaque　- The ZIPANGU Study[J]. Circ J, 2017, 81: 1611-1619.
[17]KUBO T, MATSUO Y, HAYASHI Y, et al. High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intrava-scular ultrasound study[J]. Coron Artery Dis, 2009, 20: 531-535.
[18]KUBO T, INO Y, MINTZ GS, et al. Optical coherence tomography detection of vulnerable plaques at high risk of developing acute coronary syndrome[J]. Eur Heart J Cardiovasc Imaging, 2021.doi:10.1093/ehjci/jeab028.
[19]CHIA S, RAFFEL OC, TAKANO M, et al. Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study[J]. Coron Artery Dis, 2008, 19: 237-242.
[20]RäBER L, KOSKINAS KC, YAMAJI K, et al. Changes in coronary plaque composition in patients with acute myocardial infarction treated with high-intensity statin therapy (IBIS-4): aserial optical coherence tomography study[J]. JACC Cardiovasc Imaging, 2019, 12: 1518-1528.
[21]KOMUKAI K, KUBO T, KITABATA H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study[J]. J Am Coll Cardiol, 2014, 64: 2207-2217.
[22]WANG Z, CHO YS, SOEDA T, et al. Three-dimensional morphological response of lipid-rich coronary plaques to statin therapy: a serial optical coherence tomography study[J]. Coron Artery Dis, 2016, 27: 350-356.
[23]HOU J, XING L, JIA H, et al. Comparison of intensive versus moderate lipid-lowering therapy on fibrous cap and atheroma volume of coronary lipid-rich plaque using serial optical coherence tomography and intravascular ultrasound imaging[J]. Am J Cardiol, 2016, 117: 800-806.
[24]NISHIGUCHI T, KUBO T, TANIMOTO T, et al. Effect of early pitavastatin therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome: The ESCORT Study[J]. JACC Cardiovasc Imaging, 2018, 11: 829-838.
[25]KINI AS, BABER U, KOVACIC JC, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy)[J]. J Am Coll Cardiol, 2013, 62: 21-29.
[26]HONDA S, SIDHARTA SL, SHISHIKURA D, et al. High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy[J]. Atherosclerosis, 2017, 265: 110-116.
[27]LEE SE, CHANG HJ, SUNG JM, et al. Effects of statins on coronary atherosclerotic plaques: The PARADIGM Study[J]. JACC Cardiovasc Imaging, 2018, 11: 1475-1484.
[28]NICHOLLS SJ, PURI R, ANDERSON T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV Randomized Clinical Trial[J]. JAMA, 2016, 316: 2373-2384.
[29]AKO J, HIBI K, TSUJITA K, et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome-The ODYSSEY J-IVUS Trial[J]. Circ J, 2019, 83: 2025-2033.
[30]OTA H, OMORI H, KAWASAKI M, et al. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectros-copy study[J]. Eur Heart J Cardiovasc Imaging, 2021.doi:10.1093/ehjci/jeab034.
[31]YANO H, HORINAKA S, ISHIMITSU T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome[J]. J Cardiol, 2020, 75: 289-295.
[32]GAO F, WANG ZJ, MA XT, et al. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography[J]. Lipids Health Dis, 2021, 20: 106.doi:10.1186/s12944-021-01528-3.
[33]NICCOLI G, CIN D, SCALONE G, et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstruc-tive coronary artery disease[J]. Atherosclerosis, 2016, 246: 214-220.
[34]MURAMATSU Y, MINAMI Y, KATO A, et al. Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coher-ence tomography study[J]. Int J Cardiol Heart Vasc, 2019, 24: 100382.doi:10.1016/j.ijcha.2019.100382.
[35]OMORI H, OTA H, HARA M, et al. Effect of PCSK-9 inhibitors on lipid-rich vulnerable coronary plaque asses-sed by near-infrared spectroscopy[J]. JACC Cardiovasc Imaging, 2020, 13: 1639-1641.